Evidence map›Paper›PMID 42524126›Full record

ArticleBiotechnologia2026

Evaluation of humoral and cellular immune responses induced by a novel YidRv subunit vaccine from hypervirulent

Tri Yudani M Raras, Mauludy J Ajrullah, Lailia N Rahma, Ni Nyoman T Puspaningsih, Rivo Y B Nugraha, Sumarno R Prawiro

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biotechnologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tri Yudani M RarasDepartment of Biochemistry and Molecular Biology, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
Mauludy J AjrullahMaster Program in Biomedical Science, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
Lailia N RahmaDepartment of Microbiology, Faculty of Medical and Health Science, Maulana Malik Ibrahim State Islamic University, Malang, Indonesia.
Ni Nyoman T PuspaningsihLaboratory of Proteomics, CoE Research Center for Biomolecule Engineering, Universitas Airlangga, Surabaya, Indonesia.
Rivo Y B NugrahaDepartment of Clinical Parasitology, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.
Sumarno R PrawiroDepartment of Clinical Microbiology, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Materials and methods: The capability of the purified rec-YidRv protein to induce antibody synthesis was tested using a mice model. We also assessed whether rec-YidRv could successfully trigger the proliferation of splenocytes and the synthesis of their cytokines. Furthermore, the capacity of antigen to protect mice from ESBL-producing KP strain infection was investigated. Results: Conclusions: The rec-YidRv elicited robust antibody responses and a moderate expansion of cellular activity. Rec-YidRv is an effective protein-only platform for inhibiting infection by antibiotic-resistant KP. Future studies should incorporate refined adjuvants and improved administration methods to enhance protective responses.

Indexed as

extended-spectrum β-lactamasesimmunogenicityKlebsiella pneumoniaevaccineyidRv

Identifiers

PMID42524126
PMCPMC13409365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.